Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

February 08, 2018

Novo Nordisk Launches Rebinyn in the US for People with Hemophilia B

Here is a brief preview of this blast: On February 8, 2018, Novo Nordisk officially launched REBINYN, a GlycoPEGylated, Recombinant Coagulation Factor IX, for the treatment of Hemophila B. The BLA for Rebinyn was initially approved on May 31, 2017, and is indicated for on-demand treatment and control of sporadic bleeding episodes and during surgery in adults and children with hemophilia B.